XSTEM’s Knee Osteoarthritis Stem Cell Trial: Mid-Study Update, Safety and Positive Efficacy
Source: Regen Report
Xintela has released interim data from its ongoing clinical study evaluating its stem cell product, XSTEM, in patients with knee osteoarthritis. XSTEM is an allogeneic adipose stem cell therapy, consisting of integrin α10β1-selected mesenchymal stem cells. At 18 months post-treatment, the company reports demonstrated safety and positive efficacy, including statistically significant and clinically meaningful improvements in knee pain and knee function.
